Transporters and drug-drug interactions: important determinants of drug disposition and effects.
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionPredicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical ModelsDevelopment of Human Membrane Transporters: Drug Disposition and PharmacogeneticsMarine natural products as breast cancer resistance protein inhibitorsDrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsRecent advances in understanding hepatic drug transportIn vivo and in vitro metabolites from the main diester and monoester diterpenoid alkaloids in a traditional chinese herb, the aconitum speciesDrug-induced liver injury: Towards early prediction and risk stratificationSubstrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental SubstratesInhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-GlycoproteinEsters of Bendamustine Are by Far More Potent Cytotoxic Agents than the Parent Compound against Human Sarcoma and Carcinoma CellsABC Transport Proteins in Cardiovascular Disease-A Brief Summary.The Concise Guide to PHARMACOLOGY 2013/14: transporters.Systems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cellsSalvia miltiorrhiza Roots against Cardiovascular Disease: Consideration of Herb-Drug InteractionsProtein Kinases C-Mediated Regulations of Drug Transporter Activity, Localization and Expression.Organic anion transporting polypeptide 1B3 can form homo- and hetero-oligomersStructural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brainGeneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.Xenobiotic transporter expression along the male genital tract.Differential expression and functionality of ATP-binding cassette transporters in the human hair follicle.Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain KineticsToxicological significance of renal Bcrp: Another potential transporter in the elimination of mercuric ions from proximal tubular cellsDrug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 ProteinsIntracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing).Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies.Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity.Absorptive interactions of concurrent oral administration of (+)-catechin and puerarin in rats and the underlying mechanisms.HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug DispositionNuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions.Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters.Effects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide.Eukaryotic pathways targeted by the type III secretion system effector protein, BipC, involved in the intracellular lifecycle of Burkholderia pseudomallei.SLCO1B1 variants and urine arsenic metabolites in the Strong Heart Family Study.Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy.Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.Interactions of retinoids with the ABC transporters P-glycoprotein and Breast Cancer Resistance Protein.
P2860
Q24273350-71C8F6BF-CB8A-46A4-A495-7205EF3295FBQ26764739-C8F9169D-FE30-44DA-9A7A-41C46D865D6DQ26786582-D2855A75-AC35-419E-BC23-C9CE717C470EQ27027706-D1524AAA-CDBF-4169-8E25-2865699F457DQ28071256-F4A88407-B346-4605-B2CC-2F9C48BCC270Q28077066-BEC1B5DE-CFBC-4549-9E83-80F28A4D0447Q28080742-13A40E9A-BB42-46DF-8296-730BBA56CC8EQ28468389-8E23EE8D-F592-44F2-ACA0-B6F4DF451E8FQ28547662-AF34E310-250F-42E1-89FB-0B8B558561C5Q28548692-50D82DDC-647C-4F24-BC3A-CCFD43A5D84AQ28552720-155818C6-BFD4-46A8-844C-D37FC1D05158Q30313271-7AAA6F77-37AC-4CAD-8003-05C582702831Q30486743-188C2495-2640-405C-89E2-2D3EA49F8A0EQ30833363-38BC1E89-17FB-4AA4-863B-C169998738C2Q33572234-66FBA9DB-C46A-4111-A93B-6A80F13594D3Q33624522-5E341E95-0BA2-455E-B8AD-1CBD1905BA4CQ33828993-6A24B766-1331-4C33-B81C-4B8523514392Q34053663-4FC1A9A8-09A0-4DA6-8D6E-BC47E9FCEA2CQ34116690-67FE52EF-F2F7-4E70-8237-020F772F49FFQ34125053-77C162A4-CF8E-4AC5-B5E7-8EE39817AF67Q35039217-4395B469-72E6-4698-9758-47F719239EA5Q35359647-51370B93-6985-4B07-9415-9C4025FE189CQ35444762-0F34E0D1-14AC-4AC3-A935-7648CA9FB119Q35529180-0DE6D124-339B-48A7-9E35-E213A4AC5459Q35602719-80EADB4F-455C-4DA3-938B-175C06DCDE48Q35795744-37F72536-E05F-447C-8FBA-8895499522FAQ36103626-B73F30D5-9ED9-4F0F-811C-9188EDAE571AQ36306228-BEECEC65-300B-44AE-9F4D-1985201559EBQ36362462-6B63B898-902B-4503-AAC8-D2886E2FC0FFQ36653948-B94A94A3-C46C-4714-9344-08684D36729AQ36765130-3AADFB03-EDEB-4009-A701-C2E7458B83E3Q36888037-37D3B8C6-910B-4CC9-90D9-1D7786E030F4Q37130938-852669A3-AB2F-44B7-82DA-F0EFB0718BD6Q37207759-B4D8B80C-295B-473E-859D-218E69934018Q37207803-D2C32432-303E-423A-BD12-9C29DC455BEBQ37261041-2FBDB9CC-E4B9-45EE-B519-57DE81899ACAQ37312651-4152309E-5D4B-4309-A05A-9CD28971DEE9Q37512208-53A9BC08-A530-4B43-8330-C2290BEF7F33Q37594395-C11A4F7E-68EB-4AB7-B8E9-D11C949CCCBCQ37618089-18DB17C9-6ACA-4E42-AEEB-37244D8E66D7
P2860
Transporters and drug-drug interactions: important determinants of drug disposition and effects.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Transporters and drug-drug int ...... drug disposition and effects.
@en
type
label
Transporters and drug-drug int ...... drug disposition and effects.
@en
prefLabel
Transporters and drug-drug int ...... drug disposition and effects.
@en
P2093
P356
P1476
Transporters and drug-drug int ...... drug disposition and effects.
@en
P2093
Fabian Müller
Jörg König
Martin F Fromm
P304
P356
10.1124/PR.113.007518
P577
2013-05-17T00:00:00Z